D. Boral Capital Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued a buy rating and a $32.00 price objective on the stock.

CMPX has been the topic of several other reports. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Stock Up 9.4 %

Shares of NASDAQ CMPX opened at $1.51 on Monday. The business’s 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.41. The company has a market cap of $207.76 million, a PE ratio of -4.08 and a beta of 0.89. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, research analysts anticipate that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CMPX. Rovin Capital UT ADV bought a new stake in Compass Therapeutics in the 3rd quarter valued at about $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $37,000. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics during the second quarter worth approximately $41,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.